The Effect of Germ-Line BRCA Mutations on Response to Chemotherapy and Outcome of Recurrent Ovarian Cancer
Open Access
- 1 March 2014
- journal article
- research article
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 24 (3) , 488-495
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Update on PARP1 inhibitors in ovarian cancerAnnals of Oncology, 2011
- Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencingProceedings of the National Academy of Sciences, 2011
- BRCA Mutation Status and Determinant of Outcome in Women with Recurrent Epithelial Ovarian Cancer Treated with Pegylated Liposomal DoxorubicinMolecular Cancer Therapeutics, 2011
- Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancerGynecologic Oncology, 2011
- Survival in epithelial ovarian cancer: a multivariate analysis incorporating BRCA mutation status and platinum sensitivityAnnals of Oncology, 2010
- Linking the Cellular Functions ofBRCAGenes to Cancer Pathogenesis and TreatmentAnnual Review of Pathology: Mechanisms of Disease, 2009
- “BRCAness” Syndrome in Ovarian Cancer: A Case-Control Study Describing the Clinical Features and Outcome of Patients With Epithelial Ovarian Cancer Associated With BRCA1 and BRCA2 MutationsJournal of Clinical Oncology, 2008
- The relationship between the roles of BRCA genes in DNA repair and cancer predispositionTrends in Molecular Medicine, 2002
- Clinicopathologic Features of BRCA-Linked and Sporadic Ovarian CancerJAMA, 2000
- Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population.Journal of Clinical Oncology, 1992